Delphix, Unisys Transform California State University’s Digital Strategy With Fast, Secure Data for Application Development
Hybrid-Architecture Strategy Includes Data Migration to AWS for All 23 Campuses
REDWOOD CITY, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Delphix, an industry-leading data company for DevOps, and Unisys Corporation (NYSE: UIS), a global IT solutions company, today announced that they have accelerated California State University’s (CSU) digital strategy by providing quick and secure access to data to support student application development.
The nation’s largest four-year public university can now provide its 23 campuses with data on-demand to implement their own digital strategies. This kind of rapid access has enabled software engineers at the campuses to quickly develop innovative applications to enable Graduation Initiative 2025, an ambitious project that aims to increase graduation rates while eliminating opportunity and achievement gaps. The project also includes applications that enable students to check their grades, financial aid, graduation status, etc.
The initiative is a part of the university’s larger hybrid architecture strategy aimed at improving graduation rates, student experience and satisfaction, and eliminating equity gaps in graduation rates.
Hybrid architecture Strategy
Unisys enables CSU to leverage the Delphix DevOps Data Platform to accelerate and simplify its Hybrid-Architecture enablement. The platform’s ability to easily spin up, refresh, and tear down private and public cloud-based data environments dramatically enhances the university’s application delivery pipeline.
“Using Delphix and Unisys to implement our hybrid architecture strategy allows us, for the first time, to create a unified and secure data lake, populated daily with data from all 23 campuses. This makes the data easily accessible and quickly consumable at a large scale. Our data analysts, data scientists, and developers can now drive faster innovation and proactively establish student support programs to improve graduation rates,” said Michael Berman, CIO at CSU.
The university’s hybrid architecture strategy includes data migration from an on-premise Common Management System (CMS) to Amazon Web Services (AWS), across all campuses. The CMS serves nearly 500,000 students and 56,000 faculty and staff, and is critical to everything from student enrollment, student management, scheduling, and registration to human resources, financials, and employee compensation.
“We are pleased CSU and Unisys selected AWS as a strategic cloud provider to power its digital transformation,” said Kim Majerus, Vice President, US Education, State and Local Government at AWS. “Moving to AWS can help CSU become more agile and empower them to use data more strategically to gain valuable insights that will improve the student experience. In addition, it can help the university system scale faster, reduce technical debt, realize cost savings, and manage operations more efficiently.”
Impact on Cost and Efficiency
Delphix and Unisys work together with CSU to help the university reduce costs and improve operational efficiency.
Using Delphix and Unisys, CSU has saved over $4.5M per year and avoided future costs of over $7M per year in data storage expenditures, thus freeing up resources to fund innovation. The initiative has also significantly improved CSU’s productivity measures.
- The Delphix DevOps Data Platform delivers virtual masked copies of the CMS production data on-demand, using a fraction of the storage space compared to physical data storage. This has helped Unisys reduce CSU's physical storage consumption while allowing its campuses to use self-service to clone and manipulate their data.
- Delphix’s data automation helps Unisys deliver data faster and more frequently to CSU’s campuses. The application teams can now instantly refresh copies with updated production data, rewind data to any previous point in time, and branch out data copies so data versions align with release versions, all of which dramatically improve productivity.
“We are proud to partner with Delphix to enable CSU’s hybrid architecture strategy to provide improved data delivery, data access, and data integration to better support the digital strategies at CSU,” said Rudy Gonzalez, Unisys CSU Program Director. “We remain committed to helping CSU have much greater agility to execute digital cloud strategies to better serve the campuses and improve the student experience.”
Jedidiah Yueh, Delphix CEO, added, “Transformational automation is a game-changer, enabling 100x increases in innovation velocity. Modern data automation with integrated security and compliance enables CSU to improve student outcomes and experiences, spend less on infrastructure, and invest more in strategic initiatives.”
Delphix is the industry leading data company for DevOps.
Data is critical for testing application releases, modernization, cloud adoption, and AI/ML programs. We provide an automated DevOps data platform for all enterprise applications. Delphix masks data for privacy compliance, secures data from ransomware, and delivers efficient, virtualized data for CI/CD.
Our platform includes essential DevOps APIs for data provisioning, refresh, rewind, integration, and version control. Leading companies, including Choice Hotels, J.B.Hunt, and Fannie Mae, use Delphix to accelerate digital transformation. For more information, visit www.delphix.com or follow us on LinkedIn, Twitter, andFacebook.
Unisys is a global IT solutions company that delivers successful outcomes for the most demanding businesses and governments. Unisys offerings include digital workplace solutions, cloud and infrastructure solutions, enterprise computing solutions, business process solutions and cybersecurity solutions. For more information on how Unisys delivers for its clients across the commercial, financial services and government markets, visit www.unisys.com.
Orlando de Bruce
VP of Corporate Marketing & Brand
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Aino Health AB (publ): Norberg & Partner Sustainable Group AB (publ) tecknar aktier i Aino Health AB (publ).25.1.2022 19:45:00 CET | Pressemelding
Detta pressmeddelande utgör inte ett offentligt uppköpserbjudande eller annars ett erbjudande om att förvärva aktier. Norberg & Partner Sustainable Group AB (publ)tecknar aktier i Aino Health AB (publ) och utlöser därmed budplikt. Norberg & Partner Sustainable Group AB (publ), org.nr 559268-0663 (”Norberg & Partner”) har idag tecknat 15 384 616 aktier i Aino Health AB (publ), org.nr 559063-5073 (”Aino Health”) till ett pris om 0,65 kronor per aktie. Efter förvärvet äger Norberg & Partner cirka 36,38 procent av aktierna och rösterna i Aino Health. Genom förvärvet utlöses budplikt, vilket innebär att Norberg & Partner är skyldig att offentliggöra ett budpliktsbud avseende resterande aktier i Aino Health inom fyra veckor från förvärvet, alternativt avyttra så många aktier så att aktieinnehavet representerar mindre än tre tiondelar av röstetalet för samtliga aktier i Aino Health. För ytterligare information, se Norberg & Partners hemsida. www.norbergpartner.se/ Kontaktperson: Jyrki Eklund,
Sword Group: 2021 Fourth Quarterly Results | Exceptional Profitability25.1.2022 19:15:00 CET | Press release
2021 Fourth Quarterly Results Consolidated Revenue: €59.7m Consolidated Growth: +31.8% Organic Growth: +21.9% EBITDA Margin: 15.0% RESULTS 4TH QUARTER 2021 Q4 (1) €m 2021 2020 Revenue 59.7 45.3 EBITDA 9.0 7.6 EBITDA Margin 15.0% 13.0% (1) non audited figures Organic growth on a like-for-like basis and at constant exchange rates: +21.9%. YEAR 2021 Consolidated Revenue: €214.6m Organic Growth: +21.5% EBITDA Margin: 13.6% ANALYSIS The Revenue for the Fourth Quarter of 2021 amounts to €59.7m in consolidated terms and to €55.2m without taking into account the acquisition of AiM, added to the perimeter on 1 July 2021. The EBITDA margin for the quarter amounts to 15.0% and organic growth to +21.9%. For 2021, the consolidated revenue amounts to €214.6m with an EBITDA margin of 13.6%. Organic growth for the year amounts to +21.5%. The Group established its 2021 Business Plan based on an organic growth hypothesis of 13%. Sword outperformed in terms of growth while maintaining and even exceeding
Aino Health AB (publ): The board of Aino Health resolves on a directed issue of shares to Norberg & Partner Sustainable Group AB (publ).25.1.2022 19:00:00 CET | Press release
This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail. The board of Aino Health AB (publ), reg. number 559063-5073 (the “Company”) has today, based on the authorisationfrom the annual general meeting on 24th of May 2021, resolved on a directed issue of 15 384 616 shares with deviation from the shareholders’ pre-emption right.The issue is directed to Norberg & Partner Sustainable Group AB (publ) (”Norberg & Partner”) in order to secure the Company’s long-term financing in a time-and cost-efficient manner and entails an estimated capital injection of approximately SEK 10 million. The subscription price was, after negotiations with the subscriber, determined to SEK 0.65 per new share, which corresponds to the market value as assessed by the board. The reason for the deviation from the shareholders’ pre-emptive right is to secure the Company’s long-term financing in a time- and cost-efficient manner. The new shar
Aino Health AB (publ): Styrelsen i Aino Health AB (publ) beslutar om en riktad nyemission till Norberg & Partner Sustainable Group AB (publ).25.1.2022 19:00:00 CET | Pressemelding
Styrelsen i Aino Health AB (publ), org.nr 559063-5073 (”Bolaget”) har, med stöd av bemyndigandet från årsstämman den 24 maj 2021, idag beslutat att genomföra en riktad nyemission av 15 384616 aktier med avvikelse från aktieägarnas företrädesrätt. Nyemissionen är riktad till Norberg & Partner Sustainable Group AB (publ) (”Norberg & Partner”) i syfte att säkra Bolagets långsiktiga finansiering och medför ett förväntat kapitaltillskott om ca 10 miljoner kronor. Teckningskursen har efter förhandling med teckningsberättigade fastställts till 0,65 kronor per aktie, vilket motsvarar av styrelsen bedömt marknadsvärde. Skälet till avvikelsen från aktieägarnas företrädesrätt är att emissionslikviden ska användas i syfte att på ett snabbt och kostnadseffektivt sätt stärka Bolagets långsiktiga finansiering. Betalning för de nyemitterade aktierna sker genom kontant betalning. Antalet aktier i Bolaget ökar med 15 384 616 aktier, från 26 901 155 aktier till 42 285 771 aktier. Aktiekapitalet i Bolaget
EXTRAORDINARY GENERAL MEETING APPROVES INCREASE OF CONDITIONAL CAPITAL AND SIKA PROPOSES ELECTION OF GORDANA LANDEN TO THE BOARD OF DIRECTORS25.1.2022 18:00:00 CET | Press release
EXTRAORDINARY GENERAL MEETING APPROVES INCREASE OF CONDITIONAL CAPITAL AND SIKA PROPOSES ELECTION OF GORDANA LANDEN TO THE BOARD OF DIRECTORS At an Extraordinary General Meeting, Sika’s shareholders approved the increase of conditional capital. Sika recommends the election of Gordana Landento the Board of Directors at the next Annual General Meeting, to be held on April 12, 2022. On January 25, 2022, an Extraordinary General Meeting of Sika AG was held. Based on Ordinance 3 of the Federal Council on measures to prevent the spread of COVID-19, it was not possible for shareholders to physically attend the Extraordinary General Meeting. Instead, shareholders cast their votes through the independent proxy. The shareholders approved an increase to the existing conditional capital from CHF 155,893.20 (corresponding to 15,589,320 registered shares with a par value of CHF 0.01 each) to CHF 187,893.20 (corresponding to 18,789,320 registered shares with a par value of CHF 0.01 each). Shareholder
FutureDial Automation Solutions Process Over 231 Million Preowned Mobile Phones Worldwide25.1.2022 14:30:00 CET | Press release
Growing adoption of FutureDial’s robotics and automation software by Wireless Carriers, Third-Party Logistics Providers (3PLs) and Mobile Device Recyclers led to explosive volumes of preowned iPhones and Android Smartphones being processed for resale in 2021 SUNNYVALE, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- FutureDial Incorporated continued its commanding lead in providing mobile device processing solutions for Wireless Carriers, Mobile Device Buy-Back & Trade-In Companies, Mobile Phone Recyclers and Third-Party Logistics Providers (3PLs) during the year, announcing that its robotics and automation software solutions have been used by customers in the mobile supply chain to data clear, functionally test and grade a cumulative total of over 231.4 Million pre-owned Android smartphones and iPhones worldwide, for resale on secondary markets. Additionally, the total number of functional tests using FutureDial software and robotics for quality assurance performed on preowned iPhones and A
HMNC Brain Health Expands International Patent Portfolio with Two Stress-axis Related Substances for Major Depressive Disorder25.1.2022 14:30:00 CET | Press release
In-Licensing arrangement with the renowned Max Planck Society, extends patent protection for clinical research and strengthens Nelivabon and Cortibon developmental projects The Company has also established an office in the United States, furthering global expansion strategy MUNICH, Germany, Jan. 25, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health, (“HMNC” or the “company”), a clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced that it has expanded its international patent portfolio in the field of psychiatric therapy with two patent families claiming substances for treating stress-axis related Major Depressive Disorder. These license agreements are part of a broader collaboration with the renowned Max-Planck-Society, comprising biomarker patent claims and therapeutic patent claims covering markets in Europe, the U.S., and now Asia, in particular Japan. Utilizing a more personalized approach to discovering new drugs in psychi